Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.

[1 ]Barts Cancer Institute, London, United Kingdom;

[2 ]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;

[3 ]Vall d’Hebron University Hospital Institute of Oncology (VHIO), Barcelona, Spain;

[4 ]Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;

[5 ]Yonsei University College of Medicine, Seoul, Republic of Korea;

[6 ]Seoul National University College of Medicine, Seoul, Republic of Korea;

[7 ]Ramon y Cajal University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Madrid, Spain;

[8 ]Merck & Co., Inc., Kenilworth, NJ;

[9 ]Vall d’Hebron University Hospital Institute of Oncology (VHIO) and Ramon y Cajal University Hospital, Barcelona, Spain;